

Attention-Deficit/Hyperactivity Disorder (ADHD) Medications					
Product (by brand name)	Initial and Titration Dose	Max Daily Dose	Duration of Action	Clinical Pearls	Delivery System
<b>Methylphenidate (MPH) - Immediate-Release</b>					
<b>Methylin</b> 5 mg/5 mL 10 mg/5 mL  <b>U.S. Food and Drug Administration (FDA) approved age:</b> Age 6 years and older	<b>Initial:</b> 5 mg twice daily (BID) (6 years to 17 years) 10 mg BID to three times daily (TID) (18 years and older)  <b>Titration:</b> 5 to 10 mg weekly	FDA: 60 mg	3 to 5 hours	<ul style="list-style-type: none"> <li>Take 30 to 45 minutes before meal</li> <li>Grape-flavored</li> </ul>	<ul style="list-style-type: none"> <li>Immediate-release solution</li> <li>Bioequivalent to MPH tablets</li> </ul>
<b>Methylin</b> 2.5 mg, 5 mg, 10 mg  <b>FDA approved age:</b> Age 6 years and older	<b>Initial:</b> 5 mg BID (6 years to 17 years) 10 mg BID to TID (18 years and older)  <b>Titration:</b> 5 to 10 mg weekly	FDA: 60 mg	3 to 5 hours	<ul style="list-style-type: none"> <li>Take chewable tablet with at least 8 oz of fluid at least 30 to 45 minutes before a meal</li> <li>Grape-flavored</li> </ul>	<ul style="list-style-type: none"> <li>Immediate-release tablets</li> <li>Chewable</li> <li>Bioequivalent to MPH tablets</li> </ul>
<b>Ritalin</b> 5 mg, 10 mg, 20 mg  <b>FDA approved age:</b> Age 6 years and older	<b>Initial:</b> 5 mg BID (6 years to 17 years) 10 mg BID to TID (18 years and older)  <b>Titration:</b> 5 to 10 mg weekly	FDA: 60 mg	3 to 5 hours	<ul style="list-style-type: none"> <li>Take 30 to 45 minutes before meal</li> </ul>	<ul style="list-style-type: none"> <li>Immediate-release</li> </ul>
<b>MPH - Long-Acting</b>					
<b>Adhansia XR</b> 25 mg, 35 mg, 45 mg, 55 mg, 70 mg, 85 mg  <b>FDA approved age:</b> Age 6 years and older	<b>Initial:</b> 25 mg once a day in the morning (QAM)  <b>Titration:</b> 10 to 15 mg after at least 5 days	FDA: (85 mg (children and adolescents) 100 mg (adults))	12 hours	<ul style="list-style-type: none"> <li>May open capsule and sprinkle on applesauce, then should be taken immediately without chewing</li> </ul>	Capsules contain multi-layered beads: <ul style="list-style-type: none"> <li>Immediate-release layer that contains approximately 40% of the MPH dose</li> <li>Controlled-release layer that contains approximately 80% of the MPH dose</li> </ul>
<b>Aptensio XR</b> 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg  <b>FDA approved age:</b> Age 6 years and older	<b>Initial:</b> 10 mg QAM  <b>Titration:</b> 10 mg	FDA: 60 mg	12 hours	<ul style="list-style-type: none"> <li>May open capsule and sprinkle on applesauce, then should be taken immediately without chewing</li> </ul>	Capsules contain multi layered beads: <ul style="list-style-type: none"> <li>Immediate-release layer that contains approximately 40% of the MPH dose</li> <li>Controlled-release layer that contains approximately 60% of the MPH dose</li> </ul>

ADHD Medications					
Product (by brand name)	Initial and Titration Dose	Max Daily Dose	Duration of Action	Clinical Pearls	Delivery System
<b>MPH - Long-Acting (Continued)</b>					
<p><b>Concerta</b> 18 mg, 27 mg, 36 mg, 54 mg</p> <p><b>Relexxii</b> 72 mg</p> <p><b>FDA approved age:</b> Age 6 years and older</p>	<p><b>Initial:</b> 18 mg QAM (6 years to 17 years) 18 to 36 mg QAM (18 years and older)</p> <p><b>Titration:</b> 18 mg</p>	<p>FDA: 54 mg (children) 72 mg (adolescents and adults)</p>	12 hours	<ul style="list-style-type: none"> <li>• Must be taken with fluid; swallow whole</li> <li>• Empty tablet shell may be seen in stool</li> <li>• A 72-mg dose is often more cost-effective when prescribed as two 36 mg tablets per dose</li> </ul>	<p>Osmotic delivery system surrounded by a semipermeable membrane with an immediate-release drug overcoat</p> <p>22% of total MPH available for immediate-release in drug coating</p>
<p><b>Cotempla XR-ODT</b> 8.6 mg, 17.3 mg, 25.9 mg</p> <p><b>FDA approved age:</b> Age 6 years to 17 years</p>	<p><b>Initial:</b> 17.3 mg QAM</p> <p><b>Titration:</b> Weekly increments of 8.6 to 17.3 mg</p>	FDA: 51.8 mg	12 hours	<ul style="list-style-type: none"> <li>• Allow to disintegrate on tongue without chewing or crushing</li> <li>• Grape-flavored</li> </ul>	<p>Comprises two types of MPH:</p> <ul style="list-style-type: none"> <li>• 25% immediate-release MPH</li> <li>• 75% extended-release MPH</li> </ul>
<p><b>Daytrana</b> 10 mg/9 hours 15 mg/9 hours 20 mg/9 hours 30 mg/9 hours</p> <p><b>FDA approved age:</b> Age 6 years to 17 years</p>	<p><b>Initial:</b> 10 mg/9 hours</p> <p><b>Titration:</b> Increase to next available patch strength if tolerated/response not achieved</p>	FDA: 30 mg/9 hours	12 hours (with 9 hours patch wear)	<ul style="list-style-type: none"> <li>• Do not cut patch</li> <li>• Apply at the same time each day two hours before effect is needed and wear for nine hours; effect persists three hours after removal</li> <li>• Apply to a clean, dry area of the hip, then hold in place for 30 seconds. Change application site daily</li> <li>• Do not expose application site to external heat sources (e.g., heating pads)</li> <li>• After removal, used patch should be folded so that it adheres to itself and flushed down the toilet or disposed of in a secure lidded container</li> </ul>	<p>Transdermal delivery system with 3 layers:</p> <ul style="list-style-type: none"> <li>• Protective film removed prior to application</li> <li>• Matrix delivery system with MPH embedded into the adhesive for controlled-release</li> <li>• Outside backing</li> </ul>

ADHD Medications					
Product (by brand name)	Initial and Titration Dose	Max Daily Dose	Duration of Action	Clinical Pearls	Delivery System
<b>MPH - Long-Acting (Continued)</b>					
<b>Jornay PM</b> 20 mg, 40 mg, 60 mg, 80 mg, 100 mg  <b>FDA approved age:</b> Age 6 years and older	<b>Initial:</b> 20 mg in the evening  The first dose should be administered at 8pm. Then adjust timing of administration between 6:30pm and 9:30pm to optimize the tolerability and efficacy the next morning and throughout the day.  <b>Titration:</b> 20 mg	FDA: 100 mg	Peak concentration occurs 14 hours after dose with gradual decline throughout the rest of the day	<ul style="list-style-type: none"> <li>• Can be taken whole or opened to sprinkle contents onto applesauce, then taken immediately without chewing</li> <li>• If an evening dose is missed, dose should not be administered the following morning</li> </ul>	Capsules contain beads with 2 functional film coatings: <ul style="list-style-type: none"> <li>• Outer delayed-release coating that delays the initial release of MPH</li> <li>• Inner extended-release coating controls release throughout the day due to the slow absorption in the colon</li> </ul> No more than 5% of drug is available within first 10 hours after dosing
<b>Metadate CD</b> 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg  <b>FDA approved age:</b> Age 6 years and older	<b>Initial:</b> 20 mg QAM  <b>Titration:</b> 10 to 20 mg weekly	FDA: 60 mg	8 hours	<ul style="list-style-type: none"> <li>• Take before breakfast</li> <li>• May open and sprinkle over applesauce and take without chewing, followed by a drink of water</li> <li>• Capsules or contents cannot be chewed or crushed</li> <li>• Avoid alcohol due to effects to the drug release properties</li> </ul>	Capsule contains: <ul style="list-style-type: none"> <li>• 30% immediate-release beads</li> <li>• 70% extended-release beads</li> </ul>
<b>Metadate ER</b> 10 mg and 20 mg  <b>FDA approved age:</b> Age 6 years and older	<b>Initial:</b> Replace immediate-release tablets when the 8-hour dosage corresponds to extended-release tablet size.  <b>Titration:</b> 10 mg every 3 to 7 days	FDA: 60 mg	8 hours	<ul style="list-style-type: none"> <li>• Take 30 to 45 minutes before a meal</li> <li>• Swallow whole and never crush or chew</li> </ul>	Extended-release tablets
<b>QuilliChew ER</b> 20 mg, 30 mg, 40 mg  <b>FDA approved age:</b> Age 6 years and older	<b>Initial:</b> 20 mg QAM  <b>Titration:</b> 10, 15, 20 mg weekly	FDA: 60 mg	8 hours	<ul style="list-style-type: none"> <li>• May be cut in half (20- and 30-mg tablets are scored).</li> <li>• Cherry-flavored</li> </ul>	Tablets contain: <ul style="list-style-type: none"> <li>• 30% immediate-release MPH</li> <li>• 70% extended-release MPH</li> </ul> Drug is released from sodium polystyrene sulfonate particles via ion exchange.

ADHD Medications					
Product (by brand name)	Initial and Titration Dose	Max Daily Dose	Duration of Action	Clinical Pearls	Delivery System
<b>MPH - Long-Acting (Continued)</b>					
<b>Quillivant XR</b> 25 mg/5 mL  <b>FDA approved age:</b> Age 6 years and older	<b>Initial:</b> 20 mg QAM  <b>Titration:</b> 10 to 20 mg weekly	FDA: 60 mg	12 hours	<ul style="list-style-type: none"> <li>• Must be reconstituted by pharmacist</li> <li>• Shake vigorously for at least 10 seconds prior to dose</li> <li>• Bottle sizes are 60, 120, 150, and 180 mL</li> <li>• Banana-flavored</li> <li>• Stable at room temperature for up to 4 months after reconstitution</li> <li>• Avoid alcohol</li> </ul>	Oral solution contains: <ul style="list-style-type: none"> <li>• 20% immediate-release</li> <li>• MPH 80% extended-release MPH</li> </ul>
<b>Ritalin LA</b> 10 mg, 20 mg, 30 mg, 40 mg  <b>FDA approved age:</b> Age 6 years to 12 years	<b>Initial:</b> 20 mg QAM  <b>Titration:</b> 10 mg weekly	FDA: 60 mg	6 to 9 hours	<ul style="list-style-type: none"> <li>• May open and sprinkle over cool applesauce and take immediately, then followed with a drink of water</li> <li>• Patients should avoid alcohol while taking this medication</li> </ul>	Capsules contain: <ul style="list-style-type: none"> <li>• 50% immediate-release beads</li> <li>• 50% enteric-coated, delayed-release beads</li> </ul>
<b>Dexmethylphenidate - Immediate-Release</b>					
<b>Focalin</b> 2.5 mg, 5 mg, 10 mg  <b>FDA approved age:</b> Age 6 years and older	<b>Initial:</b> 2.5 mg BID  <b>Titration:</b> 2.5 to 5 mg weekly	FDA: 20 mg	3 to 5 hours	<ul style="list-style-type: none"> <li>• Take at least 4 hours apart without regard to meals</li> <li>• D-threo enantiomer of racemic methylphenidate</li> <li>• If converting from MPH, use half of total daily dose</li> </ul>	Immediate-release tablets
<b>Dexmethylphenidate - Long-Acting</b>					
<b>Focalin XR</b> 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg  <b>FDA approved age:</b> Age 6 years and older	<b>Initial:</b> 5 mg QAM (6 years to 17 years) 10 mg QAM (18 years and older)  <b>Titration:</b> 5 mg weekly (6 years to 17 years) 10 mg weekly (18 years and older)	FDA:30 mg (6 years to 17years) 40 mg (18 years and older)	8 to 12 hours	<ul style="list-style-type: none"> <li>• May open and sprinkle over applesauce, then take immediately without chewing</li> </ul>	Capsules contain: <ul style="list-style-type: none"> <li>• 50% immediate-release beads</li> <li>• 50% enteric-coated, delayed-release beads</li> </ul>

ADHD Medications					
Product <i>(by brand name)</i>	Initial and Titration Dose	Max Daily Dose	Duration of Action	Clinical Pearls	Delivery System
<b>Dexmethylphenidate - Long-Acting</b>					
<p><b>Azstarys</b> 26.1 mg/5.2 mg 39.2 mg/7.8 mg 52.3 mg/10.4 mg</p> <p><b>FDA approved age:</b> Age 6 years and older</p>	<p><b>Initial:</b> 6 to 12 years: 39.2/7.8 mg QAM</p> <p><b>Titration:</b> After 1 week, increase to 52.3/10.4 mg or decrease to 26.1/5.2 mg based on response and tolerability</p> <p><b>Initial:</b> 13 years and older: 39.2/7.8 mg QAM</p> <p><b>Titration:</b> Increase to 52.3/10.4 mg after 1 week</p>	<p>FDA: 52.3 mg/10.4 mg</p>	<p>10 to 13 hours</p>	<ul style="list-style-type: none"> <li>• May open capsule and sprinkle on applesauce or into 2 oz. (50 mL) of water and then take immediately</li> <li>• Commercially available doses of this medication roughly correspond to 20, 30, or 40 mg of dexmethylphenidate hydrochloride</li> </ul>	<p>Capsules contain fixed molar ratios:</p> <ul style="list-style-type: none"> <li>• 30% dexmethylphenidate (immediate-release)</li> <li>• 70% serdexmethylphenidate (prodrug) converted to dexmethylphenidate slowly over several hours</li> </ul>

ADHD Medications					
Product (by brand name)	Initial and Titration Dose	Max Daily Dose	Duration of Action	Clinical Pearls	Delivery System
<b>Mixed Amphetamine Salts - Immediate-release</b>					
<b>Adderall</b> 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, 30mg  <b>FDA approved age:</b> Age 3 years and older	<b>Initial:</b> 3 years to 5 years: 2.5 mg daily 6 years and older: 5 mg daily or BID  <b>Titration:</b> 3 years to 5 years: 2.5 mg weekly 6 years and older: 5 mg weekly	FDA: 40 mg	6 hours (dose-dependent)	<ul style="list-style-type: none"> <li>Can be dosed daily to TID, 4 to 6 hours apart</li> </ul>	<ul style="list-style-type: none"> <li>Immediate-release tablets</li> <li>Combination of all 4 amphetamine salts in equal parts by weight</li> </ul>
<b>Mixed Amphetamine Salts - Immediate-release</b>					
<b>Adderall XR</b> 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg  <b>FDA approved age:</b> Age 6 years and older	<b>Initial:</b> 10 mg QAM (6 years to 17 years) 20 mg QAM (18 years and older)  <b>Titration:</b> 5 to 10 mg weekly (6 years to 12 years) 20 mg weekly (13 years and older)	FDA: 30 mg (6 years to 12 years) 20 mg (13 years and older)	10 to 12 hours	<ul style="list-style-type: none"> <li>May open and sprinkle over applesauce and taken immediately without chewing</li> <li>Patients taking divided doses of immediate-release mixed amphetamine salts,(for example, twice daily), may be switched to mixed amphetamine salts, extended-release at the same total daily dose taken once daily</li> </ul>	<ul style="list-style-type: none"> <li>Capsules contain:               <ul style="list-style-type: none"> <li>50% immediate-release beads</li> <li>50% delayed-release beads</li> </ul> </li> <li>Combination of all 4 amphetamine salts in equal parts by weight</li> </ul>

ADHD Medications					
Product (by brand name)	Initial and Titration Dose	Max Daily Dose	Duration of Action	Clinical Pearls	Delivery System
<b>Mydayis</b> 12.5 mg, 25 mg, 37.5 mg, 50 mg  <b>FDA approved age:</b> Age 13 years and older	<b>Initial:</b> 12.5 mg QAM upon awakening (13 years to 17 years)  12.5 to 25 mg QAM upon awakening (18 years to 55 years)  <b>Titration:</b> 12.5 mg weekly	FDA: 25 mg (13 years to 17years)  50 mg (18 years to 55 years)	16 hours	<ul style="list-style-type: none"> <li>• May open and sprinkle over applesauce and take immediately without chewing</li> <li>• Due to potential for insomnia (up to 16-hour duration), ensure administration upon awakening in the morning</li> <li>• If dose is missed, do not administer later in the day</li> </ul>	<ul style="list-style-type: none"> <li>• Capsules contain 3 types of beads:               <ul style="list-style-type: none"> <li>• Immediate-release beads</li> <li>• Delayed-release beads release at pH 5.5</li> <li>• Delayed-release beads release at pH 7.0</li> </ul> </li> <li>• Labeling states that 37.5 mg capsule provides similar blood concentrations to 25 mg extended-release capsule followed by 12.5 mg immediate-release tablet taken eight hours later.</li> </ul>

ADHD Medications					
Product (by brand name)	Initial and Titration Dose	Max Daily Dose	Duration of Action	Clinical Pearls	Delivery System
<b>Dextroamphetamine - Immediate-release</b>					
<b>ProCentra</b> 5 mg/5 mL  <b>FDA approved age:</b> Age 3 years to 16 years	<b>Initial:</b> 2.5 mg daily (3 years to 5 years) 5 mg daily to BID (6 years to 16 years)  <b>Titration:</b> 2.5 mg weekly (3 years to 5 years) 5 mg weekly (6 years to 16 years)	FDA: 40 mg, rarely higher	4 to 6 hours	<ul style="list-style-type: none"> <li>Bubble gum-flavored</li> <li>If dividing doses, separate by 4 to 6 hours</li> </ul>	<ul style="list-style-type: none"> <li>Immediate-release solution</li> </ul>
<b>Zenzedi</b> 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg  <b>FDA approved age:</b> Age 3 years to 16 years	<b>Initial:</b> 2.5 mg daily (3 years to 5 years) 5 mg daily to BID (6 years to 16 years)  <b>Titration:</b> 2.5 mg weekly (3 years to 5 years) 5 mg weekly	FDA: 40 mg, rarely higher	4 to 6 hours		<ul style="list-style-type: none"> <li>Immediate-release tablet</li> </ul>
<b>Dextroamphetamine - Long-Acting</b>					
<b>Dexedrine Spansule</b> 5 mg, 10 mg, 15 mg  <b>FDA approved age:</b> Age 6 years to 16 years	<b>Initial:</b> 5 mg once daily (QD) to BID  <b>Titration:</b> 5 mg weekly	FDA: 40 mg, rarely higher	6 to 8 hours		<ul style="list-style-type: none"> <li>Spansule contains an initial dose released promptly, and the remaining medication is released gradually over prolonged period</li> </ul>



ADHD Medications					
Product (by brand name)	Initial and Titration Dose	Max Daily Dose	Duration of Action	Clinical Pearls	Delivery System
<p><b>Xelstrym</b> 4.5 mg/9 hours, 9 mg/9 hours, 13.5 mg/9 hours, 18 mg/9 hours</p> <p><b>FDA approved age:</b> Age 6 years and older</p>	<p><b>Initial:</b> 4.5 mg/ 9 hours (6 years to 17 years) 9 mg/9 hours (adults)</p> <p><b>Titration:</b> 4.5 mg weekly (6 years to 17 years)</p>	FDA: 18 mg/9 hours	9 hours	<ul style="list-style-type: none"> <li>Apply system 2 hours before an effect is needed and remove within 9 hours</li> <li>Apply system to clean, dry, intact skin to any of the following application sites: hip, upper arm, chest, upper back, or flank</li> <li>Select a new application site each time a new system is applied</li> <li>Wash hands if adhesive side of transdermal system is touched</li> <li>Upon removal, fold transdermal system so that the adhesive side of the system adheres to itself and placed in a lidded container. System should not be flushed down the toilet</li> <li>Do not expose application site to external heat sources (e.g., heating pads)</li> </ul>	<p>Translucent transdermal delivery system with three layers.</p> <ul style="list-style-type: none"> <li>The first layer is an oversized protective silicone-coated, polyester release liner that is removed and discarded before applying.</li> <li>A second acrylic adhesive matrix containing dextroamphetamine.</li> <li>A third polyester and polyurethane laminate film layer (backing).</li> </ul>

ADHD Medications					
Product (by brand name)	Initial and Titration Dose	Max Daily Dose	Duration of Action	Clinical Pearls	Delivery System
<b>Amphetamine - Immediate-Release</b>					
<b>Desoxyn</b> 5 mg  <b>FDA approved age:</b> Age 6 years and older	<b>Initial:</b> 5 mg daily to BID  <b>Titration:</b> 5 mg weekly	FDA: 25 mg	4 to 5 hours	<ul style="list-style-type: none"> <li>• Insulin requirements in diabetes mellitus may be altered with use</li> <li>• Teratogenic</li> </ul>	<ul style="list-style-type: none"> <li>• Immediate-release tablets (methamphetamine)</li> </ul>
<b>Evekeo</b> 5 mg, 10 mg  <b>FDA approved age:</b> Age 3 years to 17 years	<b>Initial:</b> 2.5 mg daily (3 years to 5 years) 5 mg daily to BID (6 years to 17 years)  <b>Titration:</b> 2.5 mg weekly (3 years to 5 years) 5 mg weekly (6 years to 17 years)	FDA: 40 mg, rarely higher	At least 9.25 hours	<ul style="list-style-type: none"> <li>• Give dose on awakening and additional doses (1 to 2) at intervals of 4 to 6 hours</li> </ul>	<ul style="list-style-type: none"> <li>• Immediate-release tablets in a 1:1 ratio of dextroamphetamine/levoamphetamine</li> </ul>
<b>Evekeo ODT</b> 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg  <b>FDA approved age:</b> Age 3 years to 17 years	<b>Initial:</b> 2.5 mg daily (3 years to 5 years) 5 mg daily to BID (6 years to 17 years)  <b>Titration:</b> 2.5 mg weekly (3 years to 5 years) 5 mg weekly (6 years to 17 years)	FDA: 40 mg, rarely higher	10 hours	<ul style="list-style-type: none"> <li>• Tablet should be placed on tongue and allowed to disintegrate, do not crush or chew</li> </ul>	<ul style="list-style-type: none"> <li>• Orally disintegrating tablet in a 1:1 ratio of dextroamphetamine/levoamphetamine</li> </ul>
<b>Amphetamine - Long-Acting</b>					
<b>Adzenys XR-ODT</b> 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg  <b>FDA approved age:</b> Age 6 years and older	<b>Initial:</b> 6.3 mg QAM (6 years to 17 years) 12.5 mg once daily (QD) (18 years and older)  <b>Titration:</b> 3.1 to 6.3 mg weekly (6 years to 17 years)	FDA: 18.8 mg (6 years to 12 years) 12.5 mg (13 years and older)	13 hours	<ul style="list-style-type: none"> <li>• Tablet should be placed on tongue and allowed to disintegrate, do not crush or chew</li> <li>• Orange-flavored</li> <li>• Product is dosed as amphetamine base and is not interchangeable with other amphetamine salts on a milligram-per-milligram basis</li> </ul>	<ul style="list-style-type: none"> <li>• Orally disintegrating tablet in a 3:1 ratio of dextroamphetamine/levoamphetamine</li> <li>• Tablets contain:               <ul style="list-style-type: none"> <li>• 50% immediate-release</li> <li>• 50% delayed-release</li> </ul> </li> </ul>

ADHD Medications					
Product (by brand name)	Initial and Titration Dose	Max Daily Dose	Duration of Action	Clinical Pearls	Delivery System
<b>Dyanavel XR</b> 2.5 mg/mL  <b>FDA approved age:</b> Age 6 years and older	<b>Initial:</b> 2.5 to 5 mg QAM  <b>Titration:</b> 2.5 to 10 mg every 4 to 7 days	FDA: 20 mg	13 hours	<ul style="list-style-type: none"> <li>Do not mix with food/liquid</li> <li>Bubble gum-flavored</li> <li>Store at room temperature</li> <li>Shake vigorously before dosing and administration</li> <li>Onset in as little as 1 hour</li> <li>Product is dosed as amphetamine base and is not interchangeable with other amphetamine salts on a milligram-per-milligram basis</li> </ul>	<ul style="list-style-type: none"> <li>Extended-release suspension</li> <li>Each 1 mL contains:               <ul style="list-style-type: none"> <li>2 mg of amphetamine (in a 3.2 to 1 ratio of dextroamphetamine to levoamphetamine complexed with sodium polystyrene sulfonate)</li> <li>0.5 mg amphetamine (present as 0.3 mg of amphetamine aspartate and 0.5 mg of dextroamphetamine sulfate)</li> </ul> </li> </ul>

ADHD Medications					
Product (by brand name)	Initial and Titration Dose	Max Daily Dose	Duration of Action	Clinical Pearls	Delivery System
<b>Dyanavel XR</b> 5 mg, 10 mg, 15 mg, 20 mg  <b>FDA approved age:</b> Age 6 years and older	<b>Initial:</b> 2.5 to 5 mg QAM  <b>Titration:</b> 2.5 to 10 mg every 4 to 7 days	FDA: 20 mg	13 hours	<ul style="list-style-type: none"> <li>• May be chewed or swallowed whole</li> <li>• 5 mg tablets are scored for easy splitting</li> <li>• Bubble gum-flavored</li> <li>• Onset of action in as little as 1 hour</li> <li>• Product is dosed as amphetamine base and is not interchangeable with other amphetamine salts on a milligram-per-milligram basis</li> </ul>	<ul style="list-style-type: none"> <li>• Extended-release tablets contain immediate-release and extended-release components:               <ul style="list-style-type: none"> <li>• 80% amphetamine (present as 3.2 to 1 ratio of dextroamphetamine to levoamphetamine complexed with sodium polystyrene sulfonate)</li> <li>• 20% amphetamine (present as 0.7:1 ratio amphetamine aspartate to dextroamphetamine sulfate)</li> </ul> </li> </ul>
<b>Lisdexamfetamine - Long-Acting</b>					
<b>Vyvanse</b> 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg  <b>FDA approved age:</b> Age 6 years and older	<b>Initial:</b> 30 mg QAM  <b>Titration:</b> 10 to 20 mg weekly	FDA: 70 mg	10 to 12 hours (up to 14 hours adults)	<ul style="list-style-type: none"> <li>• May open capsule and add to yogurt, or orange juice. Must completely disperse by mixing prior to consuming mixture. Take immediately after mixing</li> </ul>	<ul style="list-style-type: none"> <li>• Capsule</li> <li>• Lisdexamfetamine dimesylate: prodrug of dextroamphetamine</li> <li>• Labeling states that product is activated primarily by red blood cells</li> </ul>

ADHD Medications					
Product (by brand name)	Initial and Titration Dose	Max Daily Dose	Duration of Action	Clinical Pearls	Delivery System
<b>Vyvanse</b> 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg  <b>FDA approved age:</b> Age 6 years and older	<b>Initial:</b> 30 mg QAM  <b>Titration:</b> 10 to 20 mg weekly	FDA: 70 mg	10 to 12 hours (up to 14 hours adults)	<ul style="list-style-type: none"> <li>• Must be chewed thoroughly before swallowing</li> <li>• Strawberry-flavored</li> </ul>	<ul style="list-style-type: none"> <li>• Chewable tablet</li> <li>• Lisdexamfetamine dimesylate: prodrug of dextroamphetamine</li> <li>• Labeling states that product is activated primarily by red blood cells</li> </ul>
Non-Stimulants - Alpha <sub>2</sub> Agonists					
<b>Kapvay</b> 0.1 mg  <b>FDA approved age:</b> Age 6 years to 17 years	<b>Initial:</b> 0.1 mg at bedtime  <b>Titration:</b> 0.1 mg weekly	FDA: 0.4 mg/day	10 to 12 hours	<ul style="list-style-type: none"> <li>• Can be added in to a psychostimulant (dose adjustment of stimulant can occur)</li> <li>• Do not crush, split, break, or chew</li> <li>• Daily doses above 0.1 mg should be divided into twice-daily dosing, with either an equal or higher dosage being given at bedtime</li> <li>• When discontinuing, taper the dose in decrements of no more than 0.1 mg every 3 to 7 days to avoid rebound hypertension</li> </ul>	<ul style="list-style-type: none"> <li>• Extended-release clonidine tablets</li> </ul>

ADHD Medications					
Product (by brand name)	Initial and Titration Dose	Max Daily Dose	Duration of Action	Clinical Pearls	Delivery System
<b>Intuniv</b> 1 mg, 2 mg, 3 mg, 4 mg  <b>FDA approved age:</b> Age 6 years to 17 years	<b>Initial:</b> 1 mg/day QAM or once a day in the evening (QPM)  <b>Titration:</b> No more than 1 mg/week to a target dose of 0.05-0.12 mg/kg/day based on clinical response and tolerability	FDA: 4 mg (6 years to 12 years)  7 mg (13 years to 17 years)	8 to 12 hours	<ul style="list-style-type: none"> <li>Do not crush/break/chew</li> <li>Do not take with high-fat meal</li> <li>Immediate-release and extended-release formulations are not interchangeable on a mg to mg basis</li> <li>When discontinuing, taper the dose in decrements of no more than 1 mg every 3 to 7 days to avoid rebound hypertension</li> </ul>	<ul style="list-style-type: none"> <li>Extended-release guanfacine tablets</li> </ul>
Non-Stimulants - Norepinephrine Reuptake Inhibitors					
<b>Strattera</b> 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg  <b>FDA approved age:</b> Age 6 years and older	<70kg: 0.5 mg/kg/day QAM for 3 days, then can be increased to 1.2mg/kg  ≥70kg: 40 mg/day for 3 days, then 80 mg/day	FDA: <70kg: 1.4 mg/kg ≥70kg: 100 mg	24 hours	<ul style="list-style-type: none"> <li>Do not crush, chew, or open capsule (contents of capsule are ocular irritants)</li> <li>CYP2D6 substrate</li> <li>Associated with hepatotoxicity</li> <li>Boxed Warning: may increase suicidal ideation in children and adolescents</li> <li>Effect may take up to 2 to 8 weeks</li> <li>Can be administered either as a single daily dose in the morning or as evenly divided doses in the morning and late afternoon/early evening. Some pharmacy plans may limit to one capsule per day</li> </ul>	<ul style="list-style-type: none"> <li>Atomoxetine immediate-release capsules</li> </ul>

ADHD Medications					
Product (by brand name)	Initial and Titration Dose	Max Daily Dose	Duration of Action	Clinical Pearls	Delivery System
<b>Qelbree</b> 100 mg, 150 mg, 200 mg  <b>FDA approved age:</b> Age 6 years to 17 years	<b>Initial:</b> 100 mg daily (6 years to 11 years) 200 mg daily (12 years to 17 years)  <b>Titration:</b> 100 mg weekly (6 years to 11 years) 200 mg weekly (12 years to 17 years)	FDA: 400 mg	24 hours	<ul style="list-style-type: none"> <li>• May be sprinkled over applesauce and consumed without chewing within 2 hours</li> <li>• CYP1A2 inhibitor; increases area under the curve (AUC) of caffeine per labeling</li> </ul>	<ul style="list-style-type: none"> <li>• Extended-release viloxazine capsules</li> </ul>
Off-Label Medications					
<b>Wellbutrin</b> 75 mg, 100 mg  <b>FDA approved age:</b> Off label	<b>Initial:</b> Less than 3 mg/kg or 150 mg/day	Off-label: Less than 6 mg/kg or 300 mg/day (no single dose >150 mg)			<ul style="list-style-type: none"> <li>• Immediate-release bupropion tablet</li> </ul>
<b>Wellbutrin SR</b> 150 mg  <b>FDA approved age:</b> Off label	<b>Initial:</b> Less than 3 mg/kg or 150 mg/day Typically dosed BID	Off-label: Less than 6 mg/kg or 300 mg/day (no single dose >150 mg)		<ul style="list-style-type: none"> <li>• Mimics bupropion TID</li> </ul>	<ul style="list-style-type: none"> <li>• Sustained-release bupropion tablets</li> </ul>
<b>Wellbutrin XL</b> 150 mg, 300 mg  <b>FDA approved age:</b> Off label	<b>Initial:</b> Less than 3 mg/kg or 150 mg/day Typically dosed daily	Off-label: Less than 6 mg/kg or 300 mg/day (no single dose >150 mg)		<ul style="list-style-type: none"> <li>• Mimics bupropion TID</li> <li>• Mimics bupropion sustained-release BID dosing</li> <li>• Empty tablet shell may be seen in stool</li> </ul>	<ul style="list-style-type: none"> <li>• Extended-release bupropion tablets</li> </ul>
<b>Catapres</b> 0.1 mg, 0.2 mg, 0.3 mg  <b>FDA approved age:</b> Off label	<b>Initial:</b> ≤45 kg: 0.05 mg at bedtime 45 kg: 1 mg at bedtime	Off-label: 2 mg (27 to 40.5 kg) 3 mg (40.5 to 45 kg) 4 mg (> 45kg)		<ul style="list-style-type: none"> <li>• Immediate-release and extended-release formulations are not interchangeable on a mg to mg basis</li> </ul>	<ul style="list-style-type: none"> <li>• Immediate-release clonidine tablets</li> </ul>

ADHD Medications					
Product (by brand name)	Initial and Titration Dose	Max Daily Dose	Duration of Action	Clinical Pearls	Delivery System
<b>Catapres-TTS</b> 0.1 mg/24 hours, 0.2 mg/24 hours, 0.3 mg/24 hours  <b>FDA approved age:</b> Off label	<b>Initial:</b> ≤45 kg: 0.05 mg at bedtime 45 kg: 1 mg at bedtime	<b>Off-label:</b> 2 mg (27 to 40.5 kg) 3 mg (40.5 to 45 kg) 4 mg (> 45kg)	Patches to be worn for 7 days	<ul style="list-style-type: none"> <li>• 2 to 3 days for results</li> </ul>	<ul style="list-style-type: none"> <li>• Transdermal film containing clonidine</li> </ul>
<b>Provigil</b> 100 mg, 200 mg  <b>FDA approved age:</b> Off label	<b>Initial:</b> 100 mg to 200 mg daily  <b>Titration:</b> May increase from 100 mg to 200 mg as tolerated on day 3	<b>Off-label:</b> Maximum dosages ranged from 200 mg to >500 mg (in divided doses) in clinical trials		<ul style="list-style-type: none"> <li>• Not approved by FDA for ADHD due to possibility for dermatologic effects (severe)</li> <li>• Dosages of 300 mg or more were typically studied in patients weighing more than 30 kg</li> </ul>	<ul style="list-style-type: none"> <li>• Immediate-release modafinil tablets</li> </ul>
Off-Label Medications (Continued)					
<b>Amantadine hydrochloride</b> 100 mg  <b>FDA approved age:</b> Off label for ADHD	<b>Initial:</b> 50 mg/day in divided doses 1 to 3 times daily (morning, noon, and 4 PM)  <b>Titration:</b> 50 mg at 4 to 7 day intervals	<b>Off-label:</b> <30 kg: 100 mg/day ≥30 kg: 150 mg/day			<ul style="list-style-type: none"> <li>• Immediate-release tablets</li> </ul>
<b>Tofranil</b> 10 mg, 25 mg, and 50 mg  <b>Tofranil PM</b> 75 mg, 100 mg, 125 mg and 150 mg  <b>FDA approved age:</b> 6 years and older	<b>Initial:</b> 1 mg/kg/day in 1 to 3 divided doses (children 6 years to 17 years)	Manufacturer's labeling warns against use of doses > 2.5 mg/kg/day in pediatric patients.  Studies have shown use of up to 4 mg/kg or 200 mg *Monitor for ECG changes			<ul style="list-style-type: none"> <li>• Tofranil immediate-release imipramine tablets</li> <li>• Tofranil PM sustained-release imipramine capsules</li> </ul>



ADHD Medications					
Product (by brand name)	Initial and Titration Dose	Max Daily Dose	Duration of Action	Clinical Pearls	Delivery System
<b>Pamelor</b> 10 mg, 25 mg, 50 mg and 75 mg <b>Nortriptyline oral solution</b> 10 mg/5mL <b>FDA approved age:</b> Off label	<b>Initial:</b> 0.5 mg/kg/day (children and adolescents) 10 mg BID (adults) <b>Titration:</b> Weekly by 0.5 mg/kg/day (children) Increase in 25 mg increments until therapeutic range is reached (3 to 4 week trial at each dose)	Off-label: Lesser of 2 mg/kg or 100 mg (children and adolescents) 50 to 150 ng/mL (adult)- Monitor plasma levels when doses above 100 mg daily are administered			<ul style="list-style-type: none"> <li>Immediate-release nortriptyline capsules</li> </ul>
Off-Label Medications (Continued)					
<b>Norpramin</b> 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg <b>FDA approved age:</b> 6 years and older Off label for ADHD	<b>Initial:</b> 1.5 mg/kg/day divided twice daily (children and adolescents) <b>Titration:</b> Weekly up to a target dose of 3.5 mg/kg/day in 2 divided doses by week 3 (children and adolescents)			<ul style="list-style-type: none"> <li>Because of reports of sudden death in children, desipramine should not be used first-line or when other TCAs are an option</li> </ul>	<ul style="list-style-type: none"> <li>Immediate-release desipramine tablets</li> </ul>

### References for Appendix 2.6: ADHD Medications

Aldon Therapeutics L.P. (2021). *Adhansia XR: Highlights of Prescribing Information*.

Amneal Pharmaceuticals, LLC. (2019). *Dexedrine Spansule: Highlights of Prescribing Information*.

Arbor Pharmaceuticals, Inc. (2021b). *Evekeo: Highlights of Prescribing Information*.

Arbor Pharmaceuticals, Inc. (2021a). *Zenzedi: Highlights of Prescribing Information*.

Biederman, J., Swanson, J. M., Wigal, S. B., Boellner, S. W., Earl, C. Q., Lopez, F. A., & Modafinil ADHD Study Group. (2006). A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: A randomized, double-blind, placebo-controlled study. *The Journal of Clinical Psychiatry*, 67(05), 727–735. <https://doi.org/10.4088/JCP.v67n0506>

Buckstein, O. (2021, November). Pharmacotherapies for attention deficit hyperactivity disorder in adults. Wolters Kluwer UpToDate, Inc.

- Centers for Medicare & Medicaid Services (CMS). (2015, October). *Stimulant and Related Medications: U.S. Food and Drug Administration-Approved Indications and Dosages for*. <https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/Downloads/stim-adult-dosingchart11-14.pdf>
- Comparison of ADHD Medications*. (2021, September). Pharmacist's Letter/Prescriber's Letter.
- Concordia Pharmaceuticals, Inc. (2020). *Kapvay: Highlights of Prescribing*. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2020/022331s0211bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022331s0211bl.pdf)
- Corium, Inc. (2021). *Azstarys: Highlights of Prescribing Information*.
- Daughton, J. M., & Kratochvil, C. J. (2009). Review of adhd pharmacotherapies: Advantages, disadvantages, and clinical pearls. *Journal of the American Academy of Child & Adolescent Psychiatry*, 48(3), 240–248. <https://doi.org/10.1097/CHI.0b013e318197748f>
- Desipramine Oral (Drug Facts and Comparisons). (2022). In *Facts and Comparisons*. Available from Wolters Kluwer Health, Inc. Facts and Comparisons
- Donfrancesco, R., Calderoni, D., & Vitiello, B. (2007). Open-label amantadine in children with attention-deficit/hyperactivity disorder. *Journal of Child and Adolescent Psychopharmacology*, 17(5), 657–663. <https://doi.org/10.1089/cap.2006.0128>
- Eli Lilly and Company. (2022). *Strattera: Highlights of Prescribing Information*. <https://pi.lilly.com/us/strattera-pi.pdf>
- FSC Laboratories, Inc. (2010). *Procentra liquid: Highlights of Prescribing Information*.
- Gomeni, R., Komolova, M., Incedon, B., & Faraone, S. V. (2020). Model-based approach for establishing the predicted clinical response of a delayed-release and extended-release methylphenidate for the treatment of attention-deficit/hyperactivity disorder. *Journal of Clinical Psychopharmacology*, 40(4), 350–358. <https://doi.org/10.1097/JCP.0000000000001222>
- Himpel, S., Banaschewski, T., Heise, C.-A., & Rothenberger, A. (2005). The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder. *Expert Opinion on Drug Safety*, 4(2), 311–321. <https://doi.org/10.1517/14740338.4.2.311>
- Ironshore Pharmaceuticals Inc. (2021). *Jornay PM: Highlights of Prescribing Information*.
- Janssen Pharmaceuticals, Inc. (2022, April). *Concerta: Highlights of Prescribing Information*. <https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/CONCERTA-pi.pdf>
- Lannett Company, Inc. (2018). *Metadate ER: (methylphenidate hydrochloride extended-release tablets, USP)*.
- Mallinckrodt, Inc. (2017). *Tofranil (imipramine): Highlights of Prescribing Information*.
- Modafinil Oral (Drug Facts And Comparisons). (2023). In *Facts and Comparisons [online]*. Available from Wolters Kluwer Health, Inc. Retrieved November 30, 2021
- Mohammadi, M.-R., Kazemi, M.-R., Zia, E., Rezazadeh, S.-A., Tabrizi, M., & Akhondzadeh, S. (2010). Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: A randomized, double-blind trial. *Human Psychopharmacology: Clinical and Experimental*, n/a-n/a. <https://doi.org/10.1002/hup.1154>
- National Library of Medicine. (2023, January 6). *XELSTRYM - dextroamphetamine patch, extended-release*. Retrieved January 12, 2023, from DAILYMED: <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0862f02a-72a8-41cc-8845-57cf4974bb6f&version=8>

- Neos Therapeutics Brands, LLC. (2021a). *Cotempla XR-ODT: Highlights of Prescribing Information*.
- Neos Therapeutics Brands, LLC. (2021b). *Adzenys XR-ODT: Highlights of Prescribing Information*.
- NextWave Pharmaceuticals, Inc. (2021). *Quillichew ER: Highlights of Prescribing Information*.
- NextWave Pharmaceuticals, Inc. (2021). *Quillivant XR: Highlights of Prescribing Information*.
- Novartis Pharmaceuticals Corporation. (2021). *Focalin: Highlights of Prescribing Information*.
- Novartis Pharmaceuticals Corporation. (2021). *Focalin XR: Highlights of Prescribing Information*.
- Novartis Pharmaceuticals Corporation. (2021). *Ritalin: Highlights of Prescribing Information*.
- Novartis Pharmaceuticals Corporation. (2021). *Ritalin LA: Highlights of Prescribing Information*.
- Noven Therapeutics, LLC. (2021). *Daytrana: Highlights of Prescribing Information*.
- Noven Therapeutics, LLC. (2022, March). *Xelstrym: Highlights of Prescribing Information*. Retrieved January 12, 2023, from [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/215401s0001bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215401s0001bl.pdf)
- Physicians Total Care, Inc. (2010). *Metadate CD: (methylphenidate HCl, USP) Extended-Release Capsules*.
- Pliszka, S. (2007). Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. *Journal of the American Academy of Child & Adolescent Psychiatry*, 46(7), 894–921. <https://doi.org/10.1097/chi.0b013e318054e724>
- Prince, J. B., Wilens, T. E., Biederman, J., Spencer, T. J., Millstein, R., Polisner, D. A., & Bostic, J. Q. (2000). A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. *Journal of Child and Adolescent Psychopharmacology*, 10(3), 193–204. <https://doi.org/10.1089/10445460050167304>
- Recordati Rare Diseases, Inc. (2019). *Desoxyn: Highlights of Prescribing Information*.
- Rhodes Pharmaceuticals L.P. (2021). *Aptensio XR: Highlights of Prescribing Information*.
- Rising Pharmaceuticals, Inc. (2021). *Methylphenidate Hydrochloride: Methylphenidate Hydrochloride Chewable Tablets, 2.5, 5 mg and 10 mg*.
- Shionogi, Inc. (2021). *Methylin: Highlights of Prescribing Information*.
- Steingard, R., Taskiran, S., Connor, D. F., Markowitz, J. S., & Stein, M. A. (2019). New formulations of stimulants: An update for clinicians. *Journal of Child and Adolescent Psychopharmacology*, 29(5), 324–339. <https://doi.org/10.1089/cap.2019.0043>
- Supernus Pharmaceuticals, Inc. (2021). *Qelbree: Highlights of Prescribing Information*. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/211964s0031bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211964s0031bl.pdf)
- Swanson, J. M. (2005). Long-acting stimulants: Development and dosing. *The Canadian Child and Adolescent Psychiatry Review*, 14(Suppl 1), 4–9. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2547091/>
- Takeda Pharmaceuticals, Inc. (2020). *Adderall XR: Highlights of Prescribing Information*.

Takeda Pharmaceuticals America, Inc. (2021b). *Intuniv: Highlights of Prescribing Information*.

Takeda Pharmaceuticals America, Inc. (2021a). *Mydayis: Highlights of Prescribing Information*.

Teva Pharmaceuticals USA, Inc. (2020). *Adderall: Highlights of Prescribing Information*.

Tris Pharma, Inc. (2021). *Dyanavel XR: Highlights of Prescribing Information*.

Vertical Pharmaceuticals, LLC. (2021). *Relexxii: Highlights of Prescribing Information*.

West-Ward Pharmaceuticals Corp. (2016). *Imipramine pamoate capsules*.

